{
    "ticker": "NBIX",
    "name": "Neurocrine Biosciences, Inc.",
    "description": "Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies to treat neurological and endocrine diseases. Founded in 1992, the company has built a robust pipeline of product candidates and commercialized products aimed at addressing unmet medical needs in the central nervous system (CNS) and hormonal disorders. Neurocrine's lead product, Ingrezza (valbenazine), is an FDA-approved treatment for tardive dyskinesia, a disorder characterized by involuntary movements often caused by long-term use of antipsychotic medications. The company is also advancing therapies for conditions such as Parkinson's disease and endometriosis, leveraging its expertise in neurobiology and drug development. Neurocrine is committed to improving the quality of life for patients suffering from debilitating conditions through transformative therapies that offer significant benefits over existing treatments. With a strong emphasis on research and clinical development, Neurocrine Biosciences continues to explore new pathways and collaborations that can enhance its portfolio and drive future growth.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "1992",
    "website": "https://www.neurocrine.com",
    "ceo": "Kevin Gorman",
    "social_media": {
        "twitter": "https://twitter.com/neurocrine",
        "linkedin": "https://www.linkedin.com/company/neurocrine-biosciences/"
    },
    "investor_relations": "https://investors.neurocrine.com",
    "key_executives": [
        {
            "name": "Kevin Gorman",
            "position": "CEO"
        },
        {
            "name": "Matt Emmens",
            "position": "Chairman"
        },
        {
            "name": "Michele A. Garfinkel",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Neurology",
            "products": [
                "Ingrezza"
            ]
        },
        {
            "category": "Endocrine",
            "products": [
                "Orilissa"
            ]
        }
    ],
    "seo": {
        "meta_title": "Neurocrine Biosciences, Inc. | Innovative Treatments for Neurological Disorders",
        "meta_description": "Explore Neurocrine Biosciences, Inc., a leader in developing therapies for neurological and endocrine diseases. Discover our products and commitment to patient care.",
        "keywords": [
            "Neurocrine Biosciences",
            "Ingrezza",
            "Neurology",
            "Endocrine",
            "Biopharmaceuticals",
            "Tardive Dyskinesia"
        ]
    },
    "faq": [
        {
            "question": "What is Neurocrine Biosciences known for?",
            "answer": "Neurocrine Biosciences is known for developing innovative therapies for neurological and endocrine disorders, including its lead product Ingrezza."
        },
        {
            "question": "Who is the CEO of Neurocrine Biosciences?",
            "answer": "Kevin Gorman is the CEO of Neurocrine Biosciences, Inc."
        },
        {
            "question": "Where is Neurocrine Biosciences headquartered?",
            "answer": "Neurocrine Biosciences is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Neurocrine's main products?",
            "answer": "Neurocrine's main products include Ingrezza for tardive dyskinesia and Orilissa for endometriosis."
        },
        {
            "question": "When was Neurocrine Biosciences founded?",
            "answer": "Neurocrine Biosciences was founded in 1992."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "PTCT",
        "ICPT"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "GILD",
        "REGN"
    ]
}